Drug Profile
Research programme: PAR-2 modulator - Peptron
Latest Information Update: 28 Mar 2018
Price :
$50
*
At a glance
- Originator Peptron
- Class Peptidomimetics
- Mechanism of Action PAR 2 receptor antagonists; PAR-2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Mar 2018 No recent reports of development identified for research development in Inflammation in South Korea
- 11 Feb 2014 Early research in Inflammation in South Korea